Avadim Introduces Breakthrough Topical Anti-Spasmodic Sports Medicine Technology
Asheville, NC (June 23, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today that [pH]UEL 5.0™, its non-toxic topical anti-spasmodic with magnesium, launched its new website https://phuel5.com.
In conjunction with the new website, [pH]UEL 5.0™ will be showcased at the 67th National Athletic Trainers Association (“NATA”) Clinical Symposia & AT Expo, in Baltimore, MD on June 22-25, 2016. According to NATA, this year’s Clinical Symposia will bring more athletic trainers under one roof than any other tradeshow.
Among the many website enhancements, you will notice a clean, modern design with easy navigation and helpful tools. The purpose of the website is to provide a useful, informative portal regarding [pH]UEL 5.0™’s technology, safety and commitment to scientific and medical research. For our customers including teams, organizations and individuals, the Company has unveiled an e-commerce platform to purchase [pH]UEL 5.0™ quickly and easily through the click of a button.
Additionally, [pH]UEL 5.0™ has added its brand ambassador campaign launching Patrick Peterson, 5-time NFL pro-bowler for the NFL’s Arizona Cardinals and the visual representation of [pH]uel5.0™ physiologic mechanism and benefits. Patrick’s likeness, reputation and personal belief in the product are clearly and visually represented. The creative theme completed by Common Thread Collective will serve to capture mental access of athletes and sports medicine influencers both nationwide and internationally.
Stephen Woody, Chairman and CEO, stated, “As part of our commitment to continuously improve our service offering to our customers, we are delighted to unveil our new website. We are excited to bring our customers a website that provides the latest and best information about all things [pH]UEL 5.0™. As with our other Pathogenesis Based Therapies, we are excited about [pH]UEL 5.0™’s ability to fill this major global gap in sports medicine.”
[pH]UEL 5.0™ has become the Official Multi-Performance Technology Partner of the Big South Conference including all eleven institutions as well as their Athletic Directors, Athletic Trainers and Coaches. [pH]UEL 5.0™’s patented therapies and protocols are being utilized and evaluated by over 500 professional, university and high school athletic teams through the United States including the St. Louis Blues, Washington Capital, University of Florida and Duke.
[pH]UEL 5.0™ has been clinically formulated to lower the pH of the skin. Scientific evidence suggests that maintaining and lowering the pH of the body’s largest organ, the skin, increases oxygen availability and uptake. Oxygen availability is a cornerstone for recovery and optimal performance.
Sports medicine continues to search for safe, effective and non-systemic solutions for Exercise-Associated Muscle Cramps (“EAMC”) and associated tightness and soreness, that have been shown to increase the risk of athletic injury and prevent optimal performance. [pH]UEL 5.0™’s patented low pH formulation has been shown to significantly reduce the incidence of EMAC and associated symptoms in the elite athlete.
For more information on [pH]UEL 5.0™ call us today at 877-677-2723 or email us at [email protected].
About [pH]UEL 5.0™:
[pH]UEL 5.0™, a division of Avadim Technologies Inc., is committed to making a difference by bringing highly differentiated technologies into the health and athletic arenas. [pH]UEL 5.0™ is a topical technology, formulated for the most difficult muscle integrity issues including muscle performance, muscle tightness, muscle recovery, muscle cramps, and flexibility. For more information, visit www.phuel5.com
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
For more information on Avadim, visit www.avadimtechnologies.com
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
David Fann, President